Cell and Gene Therapy – no matter the complexity or stage of development, accelerating your drug through the pipeline requires expertise and validated experimental model systems. Recognizing this critical need, our scientific team is delighted to showcase our advanced cell and gene therapy capabilities at the 31st Annual ESGCT Congress from October 22-25 in Rome.
Why Attend ESGCT 2024?
The ESGCT Congress is a global cornerstone for the cell and gene therapy community, attracting thousands of scientists and clinicians from industry and academia. Leading experts will share the latest trends shaping this exciting field of research. It’s an excellent opportunity to network with professionals and peers who share your interests.
Discover Scantox’s Cell and Gene Therapy Solutions at Booth D16
As a leading preclinical Contract Research Organization, we invite you to explore how our comprehensive cell and gene therapy solutions can address your project’s unique challenges. With a proven track record of over 100 successful in vitro and in vivo gene therapy studies, our expertise encompasses cutting-edge technologies such as cell therapy, adeno-associated viruses (AAVs), lentiviruses, antisense oligonucleotides (ASOs), and small interfering RNAs (siRNAs).
Join Us at The Poster Session!
To gain deeper insights into how we can support your work, attend our interactive poster session:
Poster Session II | Wednesday, 23 October | 13:30 – 15:00
1. Advancements in Preclinical Gene Therapy (Poster ID: P0290) by Shirin Sharghi
Discover our gene therapy toolkit featuring:
- Advanced surgical techniques that ensure precise viral injections into the brain and spinal cord with minimal variance and maximized reliability
- Robust analytical methods for tracking viral distribution and expression using immunohistochemistry, quantitative PCR (qPCR), ELISA and Western blots
2. Viral Gene Delivery Approach to Mimic Alpha-Synuclein Pathology in a Preclinical Model for Parkinson’s Disease (Poster ID: P0384) by Stefanie Krassnig
Explore how our in vivo model closely replicates Parkinson’s disease pathology by incorporating the A53T α-synuclein mutation using an AAV. Understand how targeted AAV injections into the substantia nigra mimic disease progression, resulting in increased α-synuclein phosphorylation and reduced dopaminergic neurons. This model provides comprehensive insights into synucleinopathies and aids in developing targeted therapies.
3. Characterization of an Inducible AAV9-hTDP-43 Mouse Model for Amyotrophic Lateral Sclerosis (Poster ID: P0354) by Benedikt Kien
Gain insight into an induced mouse model utilizing targeted human TDP-43 expression to mimic ALS pathology. This model allows for a milder, more observable disease progression – so you can better see what’s happening. Discover the valuable insights our model offers through comprehensive behavioral and histological data.
Why Contact Scantox to Elevate Your Cell and Gene Therapy Projects?
Precise and standardized methods and innovative preclinical model systems are crucial for advancing cell and gene therapies. Stefanie Krassnig, Business Development Director, emphasizes the impact of our science-first approach:
“At Scantox, we deeply validate and understand our disease models and assay solutions. We’ve refined our models to uphold the highest standards, especially in precision tasks like brain injections. By collaborating with Scantox, you gain access to state-of-the-art models and techniques that can accelerate your preclinical studies, reduce time to IND, and enhance the efficacy and safety of your gene therapies. ”
Connect With Us
We warmly invite you to:
- Visit Booth #D16
- Engage with our experts during the poster session
- Set up a one-on-one meeting with our experts – Shirin Sharghi, Stefanie Krassnig, or Benedikt Kien
- Meet us at the Molecular Mingle, an evening event designed to network and exchange ideas
Secure your spot now!
